Interestingly, we found that SLC34A2 was upregulated in immune-response (C2-C3) compared to immuno-quiet (C4-C6) signatures in tumor samples, suggesting its involvement into immunity activation. The gene discussed is SLC34A2; the disease is neoplasm.